Preludedx

2 known investors

PreludeDx develops DCISionRT, a biomarker-based diagnostic test for ductal carcinoma in situ (DCIS) breast cancer that helps physicians predict a patient's recurrence risk and whether they would benefit from radiation therapy after breast-conserving surgery. It serves oncologists and breast cancer patients within the precision diagnostics field.